Pfizer and Astellas have, this morning, announced that the addition of enzalutamide to standard androgen deprivation (ADT) has led to improved outcomes in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, ARCHES, deprivation, enzalutamide, hormone, outcome, sensitive, standard, trial | 2 Comments »
An interesting article published a couple of week’s ago in the Medical Journal of Australia reports on “real world issues” related to the implementation of active surveillance (AS) in Oz. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, AS, Australia, clinical, practice, protocol, standard, surveillance | 2 Comments »
We have known for some time that taking abiraterone acetate (Zytiga) with food (as opposed to on an empty stomach) might well allow patients to be able to take significantly lower doses of this product and gain the same clinical benefit as is currently known to be beneficial from taking 1,000 mg/day when fasting. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, dose, food, low, standard, with, without | 5 Comments »
A new article in this week’s New England Journal of Medicine has just reported the full results of the so-called PRECISION trial of MRI-targeted vs. standard biopsy techniques in the diagnosis of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, MRI, outcome, standard, targeted | 5 Comments »
Slowly but perhaps inexorably we seem to be seeing increasing scientific and clinical justification for the argument that all men thought to be at risk for a diagnosis of prostate cancer should be given an MRI scan prior to any form of prostate biopsy. … READ MORE …
Filed under: Diagnosis | Tagged: biopsy, cost, efficiency, MRI, standard | 8 Comments »
The most recent, 8th edition, of the American Joint Committee on Cancer (AJCC) Staging Manual has introduced some relatively minor modifications to the standards for staging of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: AJCC, chnge, criteria, staging, standard | 2 Comments »
In addition to the prior article on management of low-risk prostate cancer in Canada comes another article that highlights the importance of what is called “active surveillance” (as opposed to what may actually be much less sophisticated forms of monitoring). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, guideline, implementation, standard, surveillance, waiting, wtachful | 1 Comment »
“Standard of care” (SOC) is a legalistic term. As it applies to medicine, wh en a clinician follows an SOC, it means that he or she has proceeded with the reasonable caution that any minimally competent doctor would and should exercise in such circumstances. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: care, guideline, radiation, SOC, standard, therapy | 1 Comment »
An important article by Siddiqui et al. appears in this week’s issue of the Journal of the American Medical Association. It deals with the experience of Dr. Peter Pinto and his colleagues in the diagnosis of prostate cancer in about 1,000 patients over the past few years. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: biopsy, fusion, MRI, MRI/TRUS, standard, systematic | Leave a comment »
Salvage or adjuvant external beam radiation therapy for prostate cancer is usually a protracted affair, more so since we learned that a total dose of about 64 Gy to 70 Gy was needed to be effective in the salvage setting. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, hypofractionation, post-surgical, radiation, salvage, standard, stereotactic, therapy | 6 Comments »
According to a report from a major British teaching hospital, simple, standard, 1.5 T MRI scanning (without use of an endorectal coil) does not improve preoperative staging of localized prostate cancer and should not be used in this scenario. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: MRI, pre-surgical, staging, standard | 7 Comments »
It is not exactly “new” news that PSA doubling times calculated using low levels of ultrasensitive PSA data can be very different to those calulated using standard PSA values. However, a new paper has provided some additional data on this issue. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: doubling time, PSA, standard, ultasensitive | 3 Comments »
Today’s news reports include information on:
Filed under: Drugs in development, Management, Treatment | Tagged: AZD0530, conformal beam, hypofractionated, old, radiotherapy, raduical prostatectomy, standard, young | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 